A synthetic peptide from transforming growth factor-β1 Type III receptor inhibits NADPH oxidase and prevents oxidative stress in the kidney of spontaneously hypertensive rats

Antioxidants and Redox Signaling

Volumn 19, Issue 14, 2013, Pages 1607-1618

  Baltanás, Ana ^a   Miguel Carrasco, José Luis ^a   San José, Gorka ^a   Cebrián, Carolina ^a   Moreno, María U ^a   Dotor, Javier ^a   Borrás Cuesta, Francisco ^a   López, Begoña ^a   González, Arantxa ^a   Díez, Javier ^a,b   Fortuño, Ana ^a   Zalba, Guillermo ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; DISITERTIDE; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SYNTHETIC PEPTIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1 TYPE 3 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN METABOLISM; CONTROLLED STUDY; HYPERTENSION; KIDNEY; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; FIBROSIS; KIDNEY; MALE; NADPH OXIDASE; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PROTEOGLYCANS; RATS; RATS, INBRED SHR; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 84887030457     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.4653     Document Type: Article

References (48)

1. August P and Suthanthiran M. Transforming growth factor beta and progression of renal disease. Kidney Int Suppl S99-S104, 2003
2. Babelova A, Avaniadi D, Jung O, Fork C, Beckmann J, Kosowski J, Weissmann N, Anilkumar N, Shah AM, Schaefer L, Schröder K, and Brandes RP. Role of Nox4 in murine models of kidney disease. Free Radic Biol Med 53: 842-853, 2012
3. Bedard K and Krause KH. The NOX family of ROSgenerating NADPH oxidases: Physiology and pathophysiology. Physiol Rev 87: 245-313, 2007
4. Biswas SK and Lopes De Faria JB. Which come first: Renal inflammation or oxidative stress in spontaneously hypertensive rats? Free Radic Res 41: 216-224, 2007
5. Briones AM and Touyz RM. Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 12: 135-142, 2010
6. Buday A, Orsy P, Godo M, Mozes M, Kokeny G, Lacza Z, Koller A, Ungvari Z, Gross ML, Benyo Z, and Hamar P. Elevated systemic TGF-beta impairs aortic vasomotor function through activation of NADPH oxidase-driven superoxide production and leads to hypertension, myocardial remodeling, and increased plaque formation in apoEmice. Am J Physiol Heart Circ Physiol 299: H386-H395, 2010
7. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, and Wilcox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 39: 269-274, 2002
8. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, and Sorescu D. NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97: 900-907, 2005
9. Dahly AJ, Hoagland KM, Flasch AK, Jha S, Ledbetter SR, and Roman RJ. Antihypertensive effects of chronic anti-TGFbeta antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 283: R757-R767, 2002
10. Derhaschnig U, Shehata M, Herkner H, Bur A, Woisetschläger C, Laggner AN, and Hirschl MM. Increased levels of transforming growth factor-b1 in essential hypertension. Am J Hypertens 15: 207-211, 2002
11. Dikalov SI, Dikalova AE, Bikineyeva AT, Schmidt HH, Harrison DG, and Griendling KK. Distinct roles of Nox1 and Nox4 in basal and angiotensin II-stimulated superoxide and hydrogen peroxide production. Free Radic Biol Med 45: 1340-1351, 2008
12. Esparza-López J, Montiel JL, Vilchis-Landeros MM, Okadome T, Miyazono K, and Ló pez-Casillas F. Ligand binding and functional properties of betaglycan, a co-receptor of the transforming growth factor-beta superfamily. Specialized binding regions for transforming growth factor-beta and inhibin A. J Biol Chem 276: 14588-14596, 2001
13. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, and Nawata H. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 46: 1428-1437, 2003
14. Ezquerro IJ, Lasarte JJ, Dotor J, Castilla-Cortázar I, Bustos M, Peñuelas I, Blanco G, Rodríguez C, Lechuga M del C, Greenwel P, Rojkind M, Prieto J, and Borrás-Cuesta F. A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine 22: 12-20, 2003
15. Fan YY, Kohno M, Nakano D, Hitomi H, Nagai Y, Fujisawa Y, Lu XM, Fu H, Du J, Ohmori K, Hosomi N, Kimura S, Kiyomoto H, and Nishiyama A. Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats. J Hypertens 27: 1855-1862, 2009
16. Geiszt M, Kopp JB, Varnai P, and Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 97: 8010-8014, 2000
17. Hermida N, López B, González A, Dotor J, Lasarte JJ, Sarobe P, Borrás-Cuesta F, and Díez J. A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res 81: 601-609, 2009
18. Hisaki R, Fujita H, Saito F, and Kushiro T. Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats. Am J Hypertens 18: 707-713, 2005
19. Ishikawa Y, Nishikimi T, Akimoto K, Ishimura K, Ono H, and Matsuoka H. Long-Term administration of rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats. Hypertension 47: 1075-1083, 2006
20. Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, and Goldschmeding R. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53: 853-861, 1998
21. Jing L, Zhang JZ, Zhao L, Wang YL, and Guo FY. Highexpression of transforming growth factor beta1 and phosphorylation of extracellular signal-regulated protein kinase in vascular smooth muscle cells from aorta and renal arterioles of spontaneous hypertension rats. Clin Exp Hypertens 29: 107-117, 2007
22. Juárez P, Vilchis-Landeros MM, Ponce-Coria J, Mendoza V, Hernández-Pando R, Bobadilla NA, and Ló pez-Casillas F. Soluble betaglycan reduces renal damage progression in db/ db mice. Am J Physiol Renal Physiol 292: F321-F329, 2007
23. Kurashighe T, Abe K, Furusu A, Miyazaki M, Obata Y, Xia Z, Nakazawa Y, Funakoshi S, Harada T, Koji T, and Kohno S. Renoprotecive effect of azelnidipine in rats. Biol Pharm Bull 31: 2237-2244, 2008
24. Laviades C, Varo N, and Díez J. Transforming growth factor beta in hypertensives with cardiorenal damage. Hypertension 36: 517-522, 2000
25. López B, González A, Hermida N, Valencia F, De Teresa E, and Díez J. Role of lysyl oxidase in myocardial fibrosis: From Basic science to clinical aspects. Am J Physiol Heart Circ Physiol 299: H1-H9, 2010
26. Ló pez-Casillas F, Wrana JL, and Massague J. Betaglycan presents ligand to the TGF beta signaling receptor. Cell 73: 1435-1444, 1993
27. Massague J and Like B. Cellular receptors for type beta transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines. J Biol Chem 260: 2636-2645, 1985
28. Mata-Greenwood E, Grobe A, Kumar S, Noskina Y, and Black SM. Cyclic stretch increases VEGF expression in pulmonary arterial smooth muscle cells via TGF-beta1 and reactive oxygen species: A requirement for NAD(P)H oxidase. Am J Physiol Lung Cell Mol Physiol 289: L288-L289, 2005
29. Mensah GA, Croft JB, and Giles WH. The heart, kidney, and brain as target organs in hypertension. Curr Probl Cardiol 28: 156-193, 2003
30. Murillo MM, Carmona-Cuenca I, Del Castillo G, Ortiz C, Roncero C, Sánchez A, Fernández M, and Fabregat I. Activation of NADPH oxidase by transforming growth factorbeta in hepatocytes mediates up-regulation of epidermal growth factor receptor ligands through a nuclear factorkappaB-dependent mechanism. Biochem J 405: 251-259, 2007
31. Namikoshi T, Tomita N, Satoh M, Haruna Y, Kobayashi S, Komai N, Sasaki T, and Kashihara N. Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein. Am J Hypertens 20: 1085-1091, 2007
32. Ohtomo S, Nangaku M, Izuhara Y, Takizawa S, Strihou CY, and Miyata T. Cobalt ameliorates renal injury in an obese, hypertensive type 2 diabetes rat model. Nephrol Dial Transplant 23: 1166-1172, 2008
33. Onozato ML, Tojo A, Kobayashi N, Goto A,Matsuoka H, and Fujita A. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-b and NADPH oxidase in the hypertensive kidney. Nephrol Dial Transplant 22: 1314-1322, 2007
34. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, Grieve DJ, Charles RL, Eaton P, Brewer AC, and Shah AM. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 31: 1368-1376, 2011
35. Ritz E. The kidney: Both culprit and victim. Hypertension 54: 25-26, 2009
36. Santiago B, Gutierrez-Canas I, Dotor J, Palao G, Lasarte JJ, Ruiz J, Prieto J, Borrás-Cuesta F, and Pablos JL. Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol 125: 450-455, 2005
37. Schluter T, Grimm R, Steinbach A, Lorenz G, Rettig R, and Grisk O. Neonatal sympathectomy reduces NADPH oxidase activity and vascular resistance in spontaneously hypertensive rat kidneys. Am J Physiol Regul Integr Comp Physiol 291: R391-R399, 2006
38. Schröder K, Zhang M, Benkhoff S, Mieth A, Pliquett R, Kosowski J, Kruse C, Luedike P, Michaelis UR, Weissmann N, Dimmeler S, Shah AM, and Brandes RP. Nox4 is a protective reactive oxygen species generating vascular NADPH oxidase. Circ Res 110: 1217-1225, 2012
39. Tahira Y, Fukuda N, Endo M, Suzuki R, Ikeda Y, Takagi H, Matsumoto K, and Kanmatsuse K. Transforming growth factor-beta expression in cardiovascular organs in strokeprone spontaneously hypertensive rats with the development of hypertension. Hypertens Res 25: 911-918, 2002
40. Tahira Y, Fukuda N, Endo M, Ueno T, Matsuda H, Saito S, Matsumoto K, and Mugishima H. Chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor-beta1 mRNA ameliorates renal injury in hypertensive rats. J Hypertens 25: 671-678, 2007
41. Thannickal VJ and Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J Biol Chem 270: 30334-30338, 1995
42. Welch WJ, Tojo A, and Wilcox CS. Roles of NO and oxygen radicals in tubuloglomerular feedback in SHR. Am J Physiol Renal Physiol 278: F769-F776, 2000
43. Yamamoto E, Kataoka K, Dong YF, Nakamura T, Fukuda M, Tokutomi Y, Matsuba S, Nako H, Nakagata N, Kaneko T, Ogawa H, and Kim-Mitsuyama S. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice. Hypertension 54: 633-638, 2009
44. Ye H, Cai PC, ZZhou Q, and Ma WL. Transforming growth factor-b1 suppresses the up-regulation of matrix metalloproteinase-2 by lung fibroblasts in response to tumor necrosis factor-A. Wound Rep Reg 19: 392-399, 2011
45. Zhang JJ, Bledsoe G, Kato K, Chao L, and Chao J. Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 66: 722-732, 2004
46. Zhao W, Chen SS, Chen Y, Ahokas RA, and Sun Y. Kidney fibrosis in hypertensive rats: Role of oxidative stress. Am J Nephrol 28: 548-554, 2008
47. Zhou MS, Schuman IH, Jaimes EA, and Raij L. Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability. Am J Physiol Renal Physiol 295: F53-F59, 2008
48. Zhu S, Liu Y, Wang L, and Meng QH. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: Renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Nephrol Dial Transplant 23: 2841-2846, 2008